. Author manuscript; available in PMC: 2024 Dec 1.

Published in final edited form as: Clin Immunol. 2023 Oct 16;257:109809. doi: 10.1016/j.clim.2023.109809

Table 3.

Clinical efficacy of anti-HIV engineered bNAbs.

bNAb	Half-life (days)			Clinical Outcomes
bNAb	Parental Ab	Ab with LS mutation	Ref.	Therapy	Viral Load	TVR (days)	Safety
VRC01	HIV⁻ individuals: 15	71	[21,23]	Mono	0.5-fold reduction in 43% of participants [237].	ND	Yes
VRC01	HIV⁺ individuals: 12	71	[21,23]	Combined (VRC-01 LS + 10-1074)	<40 copies/ml in 44% of participants [238].	168	Yes
VRC07-523	HIV⁻ individuals: 29	40-66	[15,198] [19,239]	Mono	1.2-fold reduction in 89% of participants [237].	ND	Yes
VRC07-523	HIV⁺ individuals: 10	40-66	[15,198] [19,239]	Combined (PGDM1400 + PGT121+VRC07523 LS)	2.0-fold reduction [28].	20	Yes
N6	ND	44	[240]	Mono	1.7-fold reduction in 93% of participants [241].	35	Yes
N6	ND	44	[240]	Combined	ND	ND	ND
3BNC117	HIV⁻ individuals: 17	62	[24,242]	Mono	ND		ND
3BNC117	HIV⁺ individuals: 09	62	[24,242]	Combined (3NBC117 LS + 10-1074 LS)	1.1-2.5-fold reduction in 100% of participants [242].	ND	Yes
10-1074	HIV⁻ individuals: 24	80	[26,242]	Mono	ND		ND
10-1074	HIV⁺ individuals: 12	80	[26,242]	Combined (3NBC117 LS + 10-1074 LS)	1.1-2.5-fold reduction in 100% of participants [238,242].	ND	Yes
CAP256V2	ND	43	[238]	Mono	ND	ND	ND
CAP256V2	ND	43	[238]	Combined	ND	ND	ND
PGT121	HIV⁻ individuals: 23	74	[27,243]	Mono	ND	ND	ND
PGT121	HIV⁺ individuals: 13	74	[27,243]	Combined	ND	ND	ND

ND=data not available, TVR= Time to viral rebound; HIV⁺ individuals = Viremic patients without ART; LS=M428L and N434S.